Regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2 - Scientific guideline

This reflection paper outlines the quality, nonclinical and clinical data that would be required to support approval of a variant vaccine, whether monovalent or multivalent.

The requirements apply only when both of the following criteria are met:

• The parent vaccine has been granted marketing authorisation in the EU;
• Except for the SARS-CoV-2 antigen(s) to be presented to the human immune system following vaccination, the manufacturing process and controls and the facilities for vaccine production of the variant vaccine, are the same or very similar to those for the parent vaccine.

Keywords: COVID-19, SARS-CoV-2, vaccine, regulatory requirements, variant strain, variant vaccine, parent vaccine, immunogenicity, quality, nonclinical, multivalent

Documents

Reflection paper on the regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2

AdoptedReference Number: EMA/117973/2021

Related content

• Multidisciplinary: vaccines
• Adapting COVID-19 vaccines to SARS-CoV-2 variants: guidance for vaccine manufacturers(25/02/2021)
• COVID-19 guidance: assessment and marketing authorisation
• COVID-19 vaccines: key facts
• Clinical evaluation of new vaccines
• Guideline on good pharmacovigilance practices (GVP): Product- or population-specific considerations I: Vaccines for prophylaxis against infectious diseases